| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 10/17/2001 | CN1072963C Vaccine compsns. |
| 10/17/2001 | CN1072962C Infections bursal disease vaccine |
| 10/16/2001 | USRE37410 Controlled local delivery of chemotherapeutic agents for treating solid tumors |
| 10/16/2001 | US6303771 Pth |
| 10/16/2001 | US6303765 Polynucleotide which codes for protein of defined amino acids sequence; recombinant production; anticarcinogenic agents; antiarthritic agents; treatment of immune disorders such as multiple sclerosis and myasthenia gravis; diagnosis |
| 10/16/2001 | US6303755 Therapeutic multispecific compounds comprised of anti-FCA receptor antibodies |
| 10/16/2001 | US6303661 Orally administering inhibitor of dipeptidyl peptidase (dp iv) or of dipeptidyl peptidase iv-like activity |
| 10/16/2001 | US6303580 Cyclitol Containing carbohydrates from human tissue which regulate lipogenic activity |
| 10/16/2001 | US6303572 Control of acidic gut syndrome |
| 10/16/2001 | US6303571 To screen for antibacterial compounds; genetic immunization; therapy and prophylaxis |
| 10/16/2001 | US6303347 Vaccines |
| 10/16/2001 | US6303331 Vertebrate apoptosis gene: compositions and methods |
| 10/16/2001 | US6303321 Methods for diagnosing sepsis |
| 10/16/2001 | US6303318 Detecting urogenital hyperplasia; isolate proteases in sample, detecting and classify preferential proteases in sample, compare to control, amplified enzyme concentration indicates hyperplasia |
| 10/16/2001 | US6303292 Geneticlly engineered viral polypeptides; for use in diagnosis and treatment of viral infection |
| 10/16/2001 | US6303130 Pasteurella haemolytica vaccine inactivated by ultraviolet light |
| 10/16/2001 | US6303129 Production of borrelia burgdorferi vaccine, product produced thereby and method of use |
| 10/16/2001 | US6303128 Method for protein expression |
| 10/16/2001 | US6303124 Compounds |
| 10/16/2001 | US6303123 Which bind and neutralize the hormone gnrh in vivo. |
| 10/16/2001 | US6303121 Method of using human receptor protein 4-1BB |
| 10/16/2001 | US6303120 Inducing antibodies in a subject to an allyl-substituted pentasaccharide by administering the compound conjugated to a protein carrier at its allyl group. |
| 10/16/2001 | US6303118 Human chitinase, its recombinant production, its use for decomposing chitin, its use in therapy or prophylaxis against infection diseases |
| 10/16/2001 | US6303114 IL-12 enhancement of immune responses to T-independent antigens |
| 10/16/2001 | CA2036463C Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines |
| 10/16/2001 | CA2031164C Recombinant herpesvirus of turkeys and live vector vaccines derived thereof |
| 10/16/2001 | CA1341305C Dna binding proteins including androgen receptor |
| 10/12/2001 | CA2322368A1 Animal model for allergic disorders |
| 10/11/2001 | WO2001075454A2 Diagnosis and treatment of alzheimer's disease |
| 10/11/2001 | WO2001075170A1 A functional assay of high-density lipoprotein |
| 10/11/2001 | WO2001075168A1 Control of a gene induced by oxidized lipids in human artery wall cells |
| 10/11/2001 | WO2001075114A2 Chlamydia transmembrane protein as antigen, corresponding dna fragments and uses thereof |
| 10/11/2001 | WO2001075113A2 Chlamydia myosin heavy chain homolog as antigen, corresponding dna fragments and uses thereof |
| 10/11/2001 | WO2001075112A2 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 10/11/2001 | WO2001075111A2 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 10/11/2001 | WO2001075110A2 Mucin-1 specific binding members and methods of use thereof |
| 10/11/2001 | WO2001075109A2 Antagonist antibodies to ve-cadherin without adverse effects on vascular permeability |
| 10/11/2001 | WO2001075108A1 Human ion channel protein and polynucleotides encoding the same |
| 10/11/2001 | WO2001075096A1 Isolated and purified nonpeptide antigens from mycobacterium tuberculosis |
| 10/11/2001 | WO2001075074A1 Novel proteins |
| 10/11/2001 | WO2001075073A2 Prostate cell lines and their use |
| 10/11/2001 | WO2001075072A2 PRODUCTION OF TcR GAMMA DELTA T CELLS |
| 10/11/2001 | WO2001074904A2 G-protein coupled receptors and nucleic acids encoding same |
| 10/11/2001 | WO2001074903A2 CD20/IgE-RECEPTOR LIKE MOLECULES AND USES THEREOF |
| 10/11/2001 | WO2001074900A2 Nuclear factor kb inducing factor |
| 10/11/2001 | WO2001074863A2 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 10/11/2001 | WO2001074859A2 A gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| 10/11/2001 | WO2001074856A2 Wnt-7b-like polypeptides and nucleic acids encoding same |
| 10/11/2001 | WO2001074855A2 Compositions and methods for dendritic cell-based immunotherapy |
| 10/11/2001 | WO2001074848A2 Immunodominant acetylcholine receptor alpha subunit peptides, complexes thereof with mhc class ii components and their use |
| 10/11/2001 | WO2001074847A2 T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer |
| 10/11/2001 | WO2001074845A2 Immunogenic peptides derived from prostate-specific membrane antigen (psma) and uses thereof |
| 10/11/2001 | WO2001074404A2 Compositions containing genetically modified lung cancer cells expressing a tgf-beta inhibitor |
| 10/11/2001 | WO2001074388A1 Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma |
| 10/11/2001 | WO2001074387A1 Use of aliphatic quaternary ammonium as adjuvant in a pharmaceutical composition administered by mucosal delivery |
| 10/11/2001 | WO2001074386A2 Cold-adapted equine influenza viruses |
| 10/11/2001 | WO2001074382A1 Method of treatment using ligand-immunogen conjugates |
| 10/11/2001 | WO2001074375A1 Composition for treatment of autoimmune disease |
| 10/11/2001 | WO2001074349A1 Butylnitrone containing compositons for inhibition of cancer development |
| 10/11/2001 | WO2001074317A1 Methods of modulating hair growth |
| 10/11/2001 | WO2001074299A2 Compositions and methods for inhibition of cancer invasion and angiogenesis |
| 10/11/2001 | WO2001074296A2 Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists |
| 10/11/2001 | WO2001074164A1 Methods of modulating hair growth |
| 10/11/2001 | WO2001066139A8 Use of a compound that selectively binds to cd123 to impair hematologic cancer progenitor cell |
| 10/11/2001 | WO2001049319A8 Composition containing bacterial antigens, used for the prophylaxis and the treatment of allergic diseases |
| 10/11/2001 | WO2001049317A3 Enhancing the immune response to an antigen by presensitizing with an inducing agent prior to immunizing with the inducing agent and the antigen |
| 10/11/2001 | WO2001045746A3 Methods and compositions for prolonging elimination half-times of bioactive compounds |
| 10/11/2001 | WO2001032702A9 Molecular structure of rhd negative locus |
| 10/11/2001 | WO2001031003B1 Cloning, expression and characterisation of a gene expressed in tumour cells and involved in the regulation of the immune response |
| 10/11/2001 | WO2001025269A3 Human g-protein coupled receptor |
| 10/11/2001 | WO2001024763A3 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| 10/11/2001 | WO2001023587A3 Serine protease |
| 10/11/2001 | WO2001022994A3 Vaccines against neisseria infection |
| 10/11/2001 | WO2001021799B1 Traf4 associated cell cycle proteins, compositions and methods of use |
| 10/11/2001 | WO2001021655A3 Virulence gene and protein, and their use |
| 10/11/2001 | WO2001021202A3 Treatment of chronic inflammatory disease by inhibiting sub-groups of activated t-cells |
| 10/11/2001 | WO2001020025A3 Polymorphisms in the human cyp3a4 and cyp3a7 genes and their use in diagnostic and therapeutic applications |
| 10/11/2001 | WO2001007625A3 Ehrlichia canis genes and vaccines |
| 10/11/2001 | WO2001004143A3 Prostase vaccine |
| 10/11/2001 | WO2000057908A9 Attenuated dengue-1 virus vaccine |
| 10/11/2001 | WO2000047222A3 Inactivated influenza virus vaccine for nasal or oral administration |
| 10/11/2001 | WO2000045823A9 Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo |
| 10/11/2001 | WO2000026240A3 Streptococcal alpha2m-binding protein |
| 10/11/2001 | US20010029295 Isolated polynucleotide |
| 10/11/2001 | US20010029293 Icam-related protein |
| 10/11/2001 | US20010029251 Administering cytomegalo virus protein |
| 10/11/2001 | US20010029043 Prokaryotic; transformed with nucleic acid encoding papillomavirus virus major capsid protein that assembles within, such as Salmonella, to form chimeric virus like particles; anticancer, antitumor vaccine |
| 10/11/2001 | US20010029041 Isolated, live, attenuated phenotype useful for stimulating protective immune response without producing severe symptoms; respiratory stress |
| 10/11/2001 | US20010029031 Polynucleotides encoding human sodium bicarbonate cotransporters |
| 10/11/2001 | US20010029020 In vitro determination of metastatic stomach, esophageal, and colorectal cancer from sampling cells outside of the colorectal track for gene transcript or protein |
| 10/11/2001 | US20010029019 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin |
| 10/11/2001 | US20010028885 Bovine footrot treatment and prevention |
| 10/11/2001 | US20010028884 Vaccination against canine herpesvirosis and vaccines therefor |
| 10/11/2001 | US20010028883 Papillomavirus cellular receptor |
| 10/11/2001 | US20010028882 Anti-cryptosporidium parvum preparations |
| 10/11/2001 | EP1144001A3 Inactivated influenza virus vaccine for nasal or oral administration |
| 10/11/2001 | DE19964162A1 Verfahren zur Abtötung, Abschwächung und Veränderung von Bakterien, Bakteriophagen, Viren, Virophagen, Prionen und Pilzen mit hohen Drücken Method of killing, mitigation and change of bacteria, bacteriophages, viruses, Virophage, prions and fungi with high pressures |
| 10/11/2001 | CA2413211A1 A gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| 10/11/2001 | CA2405484A1 Immunodominant acetylcholine receptor alpha subunit peptides, complexes thereof with mhc class ii components and their use |
| 10/11/2001 | CA2405299A1 Method of treatment using ligand-immunogen conjugates |